 | |
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C25H26N4O4 |
| Molar mass | 446.507 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Otamixaban (INN) is an experimental injectableanticoagulantdirect factor Xa inhibitor[1] that was investigated for the treatment foracute coronary syndrome. In 2013,Sanofi announced that it had endeddevelopment of the drug candidate after poor performance in aPhase III clinical trial.[2][3]
Sanofi is ending development on two compounds, the anticancer compound iniparib and the anticoagulant otamixaban, both of which flunked Phase III studies.
 | Thisdrug article relating to theblood andblood forming organs is astub. You can help Wikipedia byexpanding it. |
